ES2121103T3 - Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas. - Google Patents

Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.

Info

Publication number
ES2121103T3
ES2121103T3 ES94102791T ES94102791T ES2121103T3 ES 2121103 T3 ES2121103 T3 ES 2121103T3 ES 94102791 T ES94102791 T ES 94102791T ES 94102791 T ES94102791 T ES 94102791T ES 2121103 T3 ES2121103 T3 ES 2121103T3
Authority
ES
Spain
Prior art keywords
angiotensin
antagonists
treatment
viral diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94102791T
Other languages
English (en)
Inventor
Akira Matsumori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2121103T3 publication Critical patent/ES2121103T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

UN COMPUESTO ANTAGONISTA DE LA ANGIOTENSINA II QUE SE ADMINISTRA A MAMIFEROS CON ENFERMEDADES VIRALES. ESTA ADMINISTRACION MEJORA LOS DAÑOS CAUSADOS A LAS CELULAS ASOCIADOS AL VIRUS, PRODUCIENDO EFECTOS TERAPEUTICOS EN ENFERMEDADES VIRALES. ESTE COMPUESTO ES UTIL TAMBIEN PARA LA PREVENCION DE TALES ENFERMEDADES.
ES94102791T 1993-02-26 1994-02-24 Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas. Expired - Lifetime ES2121103T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3823493 1993-02-26

Publications (1)

Publication Number Publication Date
ES2121103T3 true ES2121103T3 (es) 1998-11-16

Family

ID=12519615

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94102791T Expired - Lifetime ES2121103T3 (es) 1993-02-26 1994-02-24 Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.

Country Status (8)

Country Link
US (2) US5605919A (es)
EP (1) EP0612524B1 (es)
JP (1) JP2787539B2 (es)
AT (1) ATE170076T1 (es)
CA (1) CA2116388C (es)
DE (1) DE69412662T2 (es)
DK (1) DK0612524T3 (es)
ES (1) ES2121103T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6037456A (en) * 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EP1262180A4 (en) 2000-02-18 2005-06-01 Takeda Pharmaceutical TNF-ALPHA HEMMER
US20060135422A1 (en) * 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
DE602006016313D1 (de) 2005-09-16 2010-09-30 Arrow Therapeutics Ltd Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
CL2008000868A1 (es) * 2007-03-28 2008-10-10 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un compuesto derivado de benzimidazol y un agente de control de ph; metodo de estabilizacion y de mejoramiento de la disolucion; uso de un agente de control de ph.
US9066951B2 (en) * 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
WO2010127246A2 (en) * 2009-04-30 2010-11-04 Burnham Institute For Medical Research Hnf4 modulators and methods of use
JP2020523389A (ja) * 2017-06-13 2020-08-06 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 抗ウイルス薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1076582A (en) * 1975-10-28 1980-04-29 Charles J. Paget Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
US4420479A (en) * 1982-04-08 1983-12-13 Eli Lilly And Company Olefinic benzimidazoles, formulations, and antiviral methods
CA1279648C (en) * 1986-07-11 1991-01-29 Haruo Kuriyama 2-(4-pyridylaminometyl)-benzimidazole derivatives having antiviral activity
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
HU9203505D0 (en) * 1990-06-01 1993-01-28 Du Pont Merck Pharma 1,4-diamino-2,3-dihydroxi-butane compounds
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases

Also Published As

Publication number Publication date
JP2787539B2 (ja) 1998-08-20
ATE170076T1 (de) 1998-09-15
US5750551A (en) 1998-05-12
DE69412662D1 (de) 1998-10-01
EP0612524B1 (en) 1998-08-26
US5605919A (en) 1997-02-25
JPH06305965A (ja) 1994-11-01
CA2116388A1 (en) 1994-08-27
DE69412662T2 (de) 1999-01-07
EP0612524A1 (en) 1994-08-31
CA2116388C (en) 2007-03-13
DK0612524T3 (da) 1999-05-25

Similar Documents

Publication Publication Date Title
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ES2121103T3 (es) Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.
BG103521A (en) Substituted pyrimidinon and pyridon compounds and methods for their application
DK1941904T3 (da) TNF-antagonister til anvendelse i supplementsterapi til methotrexat i behandlingen af autoimmune sygdomme
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
DE69129248D1 (de) Peptide mit Endothelin antagonistischer Aktivität, deren Herstellung und pharmazeutische Zusammensetzungen
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
LU90562I2 (fr) Acides imidazoalc-noiques
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
ATE309249T1 (de) Chemokin rezeptor antagonisten und verwndung
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
ATE227717T1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
ES2139673T3 (es) Utilizacion de norastemizol para el tratamiento de rinitis alergica.
IL161889A0 (en) Method for treating diseases with omega interferon
NO20003313D0 (no) Terapeutiske midler
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff
WO2001009119A3 (en) Chemokine receptor antagonists

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612524

Country of ref document: ES